1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. California >
  6. Aravive Acquires Versartis

M&A Deal Summary

Aravive Acquires Versartis

On June 4, 2018, Aravive acquired life science company Versartis

Acquisition Highlights
  • This is Aravive’s 1st transaction in the Life Science sector.
  • This is Aravive’s 1st transaction in the United States.
  • This is Aravive’s 1st transaction in California.

M&A Deal Summary
Date 2018-06-04
Target Versartis
Sector Life Science
Buyer(s) Aravive
Deal Type Merger

Target

Versartis

Menlo Park, California, United States
Versartis, Inc. is an endocrine-focused biopharmaceutical company focused on developing novel, long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. Versartis was formed in 2008 and is based in Menlo Park, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Aravive

Houston, Texas, United States
Category Company
Founded 2008
Sector Life Science
Employees17
Revenue 7M USD (2021)
DESCRIPTION

Aravive is a clinical-stage biopharmaceutical company focused on developing novel, highly selective therapies designed to treat serious cancers and certain fibrotic diseases. Aravive was founded in 2008 and is based in Houston, Texas.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal